Article Text

PDF
Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration
  1. G Mojica1,
  2. S M Hariprasad2,
  3. R D Jager2,
  4. W F Mieler2
  1. 1
    University of Chicago Pritzker School of Medicine, Chicago, IL, USA
  2. 2
    Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL, USA
  1. S M Hariprasad, Department of Ophthalmology and Visual Science, University of Chicago, 5841 South Maryland, MC 2114, Chicago, IL 60637, USA; retina{at}uchicago.edu

Statistics from Altmetric.com

Rosenfeld and colleagues reported that ranibizumab (Lucentis) had no long-term effect on intraocular pressure (IOP) as determined by monthly measurements during the 2-year MARINA study.1 We are unaware of previous studies examining the short-term effect on IOP by intravitreal ranibizumab in patients with wet age-related macular degeneration.

Methods

We conducted a retrospective chart review of 50 ranibizumab injections from 23 patients. IOP was recorded using Goldmann applanation tonometry. All patients included in this series received ranibizumab injection as directed by the instructions provided in the package insert (volume …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.